Theravance Biopharma to Participate in an Upcoming Investor Conference

Rhea-AI Summary

Theravance Biopharma (NASDAQ: TBPH) has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference in New York City. The company will engage in a Fireside Chat on Tuesday, September 10 at 10:00 am ET (7:00 am PT/3:00 pm IST). Additionally, Theravance Biopharma will host in-person meetings with the investment community during the conference.

Investors and interested parties can access a webcast of the event through the company's website, Theravance.com, under the Investors section, Events and Presentations. The webcast replay will be available on the company's website for 30 days following the event, providing an opportunity for those unable to attend live to catch up on the discussion.

DUBLIN, Aug. 27, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference in New York City on Tuesday, September 10 at 10:00 am ET (7:00 am PT/3:00 pm IST) and will be hosting in-person meetings with the investment community at the conference. 

Webcast of the event may be accessed by visiting Theravance.com, under the Investors section, Events and Presentations. Replay of the webcast will be archived on the Company's website for 30 days.

About Theravance Biopharma

Theravance Biopharma, Inc.'s focus is to deliver Medicines that Make a Difference^® in people's lives. In pursuit of its purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI^® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Ampreloxetine, its late-stage investigational once-daily norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA), has the potential to be a first in class therapy effective in treating a constellation of cardinal symptoms in MSA patients. The Company is committed to creating/driving shareholder value.

For more information, please visit www.theravance.com.

THERAVANCE BIOPHARMA^®, THERAVANCE^® and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries).

YUPELRI^® is a registered trademark of Mylan Specialty L.P., a Viatris company. Trademarks, trade names or service marks of other companies appearing in this press release are the property of their respective owners.

Contact:
investor.relations@theravance.com
650-808-4045

View original content to download multimedia:https://www.prnewswire.com/news-releases/theravance-biopharma-to-participate-in-an-upcoming-investor-conference-302231359.html

SOURCE Theravance Biopharma, Inc.

FAQ

When is Theravance Biopharma (TBPH) participating in the H.C. Wainwright Global Investment Conference?

Theravance Biopharma (TBPH) is participating in the H.C. Wainwright 26th Annual Global Investment Conference on Tuesday, September 10, with a Fireside Chat scheduled for 10:00 am ET.

Where can I watch the webcast of Theravance Biopharma's (TBPH) Fireside Chat?

The webcast of Theravance Biopharma's (TBPH) Fireside Chat can be accessed on the company's website, Theravance.com, under the Investors section, Events and Presentations.

How long will the replay of Theravance Biopharma's (TBPH) conference webcast be available?

The replay of Theravance Biopharma's (TBPH) conference webcast will be archived on the company's website for 30 days following the event.

What type of investor engagement is Theravance Biopharma (TBPH) offering at the conference?

Theravance Biopharma (TBPH) will be hosting in-person meetings with the investment community at the H.C. Wainwright Global Investment Conference, in addition to participating in a Fireside Chat.